Women of child-bearing potential.

History of angioedema, drug-related or otherwise

History of hypersensitivity to LCZ696, valsartan, or drugs of similar chemical classes.

Severe hypertension (grade 3 of WHO classification; msDBP ≥100 mmHg and/or msSBP ≥ 180 mmHg) at screening or at the end of the washout period.

History or evidence of a secondary form of hypertension,

Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or any history of stroke.

History of myocardial infarction, coronary bypass surgery or percutaneous coronary intervention (PCI) during 12 month prior to screening.

Current or history of hypertensive retinopathy.

Previous or current diagnosis of heart failure (NYHA Class II-IV).

Clinically significant valvular heart disease at screening.

Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension